These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 15054036)

  • 21. [Effect of recombinant human G-CSF combined with EPO in treatment of patients with MDS].
    Li ZY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Jun; 13(3):512-3. PubMed ID: 15972155
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model.
    Hellström-Lindberg E; Negrin R; Stein R; Krantz S; Lindberg G; Vardiman J; Ost A; Greenberg P
    Br J Haematol; 1997 Nov; 99(2):344-51. PubMed ID: 9375752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Failure of combination therapy with recombinant granulocyte colony-stimulating factor and erythropoietin in myelodysplastic syndromes.
    Imamura M; Kobayashi M; Kobayashi S; Yoshida K; Mikuni C; Ishikawa Y; Matsumoto S; Sakamaki S; Niitsu Y; Hinoda Y
    Ann Hematol; 1994 Apr; 68(4):163-6. PubMed ID: 7516190
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Haematopoietic growth factors in the treatment of myelodysplastic syndromes.
    Cazzola M
    Forum (Genova); 1999; 9(1):49-57. PubMed ID: 10101210
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach.
    Mundle S; Lefebvre P; Vekeman F; Duh MS; Rastogi R; Moyo V
    Cancer; 2009 Feb; 115(4):706-15. PubMed ID: 19152429
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical efficacy analysis of recombinant human erythropoietin in the treatment of lower-risk myelodysplastic syndromes].
    Zhang H; Qin T; Xu Z; Fang L; Pan L; Hu N; Qu S; Zhang Y; Xiao Z
    Zhonghua Xue Ye Xue Za Zhi; 2014 Jan; 35(1):18-23. PubMed ID: 24602726
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Spontaneous and cytokine-induced thrombocytopenia in myelodysplastic syndromes: serum thrombopoietin levels and bone marrow morphology. Scandinavian MDS Group, Sweden and Norway.
    Hellström-Lindberg E; Kanter-Lewensohn L; Nichol J; Ost A
    Br J Haematol; 1999 Jun; 105(4):966-73. PubMed ID: 10554808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life.
    Hellström-Lindberg E; Gulbrandsen N; Lindberg G; Ahlgren T; Dahl IM; Dybedal I; Grimfors G; Hesse-Sundin E; Hjorth M; Kanter-Lewensohn L; Linder O; Luthman M; Löfvenberg E; Oberg G; Porwit-MacDonald A; Rådlund A; Samuelsson J; Tangen JM; Winquist I; Wisloff F;
    Br J Haematol; 2003 Mar; 120(6):1037-46. PubMed ID: 12648074
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recombinant human erythropoietin treatment for chemotherapy-related anemia in children.
    Varan A; Büyükpamukçu M; Kutluk T; Akyüz C
    Pediatrics; 1999 Feb; 103(2):E16. PubMed ID: 9925862
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response.
    Villegas A; Arrizabalaga B; Fernández-Lago C; Castro M; Mayans JR; González-Porras JR; Duarte RF; Remacha AF; Luño E; Gasquet JA
    Curr Med Res Opin; 2011 May; 27(5):951-60. PubMed ID: 21381892
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of rHuEpo in low-risk myelodysplastic syndrome patients.
    Rigolin GM; Castoldi G
    Leuk Lymphoma; 2005 Jun; 46(6):823-31. PubMed ID: 16019526
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sequential administration of recombinant human granulocyte-macrophage colony-stimulating factor and human erythropoietin for treatment of myelodysplastic syndromes.
    Runde V; Aul C; Ebert A; Grabenhorst U; Schneider W
    Eur J Haematol; 1995 Jan; 54(1):39-45. PubMed ID: 7859874
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions.
    Nilsson-Ehle H; Birgegård G; Samuelsson J; Antunovic P; Astermark J; Garelius H; Engström LM; Kjeldsen L; Nilsson L; Olsson A; Skov-Holm M; Wallvik J; Gulbrandsen N; Hellström-Lindberg E
    Eur J Haematol; 2011 Sep; 87(3):244-52. PubMed ID: 21623919
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Investigation for the presence of anti-erythropoietin antibodies in patients with myelodysplastic syndromes.
    Voulgari PV; Hatzimichael EC; Tsiara S; Tzallas C; Drosos AA; Bourantas KL
    Eur J Haematol; 2001 Jan; 66(1):31-6. PubMed ID: 11168505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant human granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin may improve anemia in selected patients with myelodysplastic syndromes.
    Hansen PB; Johnsen HE; Hippe E; Hellström-Lindberg E; Ralfkiaer E
    Am J Hematol; 1993 Dec; 44(4):229-36. PubMed ID: 8237992
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of erythropoietin in the anemia of myelodysplastic syndrome.
    Stein RS
    Clin Lymphoma; 2003 Aug; 4 Suppl 1():S36-40. PubMed ID: 14556674
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromes.
    Giraldo P; Nomdedeu B; Loscertales J; Requena C; de Paz R; Tormo M; Navarro P; Benedit P; Gasquet JA;
    Cancer; 2006 Dec; 107(12):2807-16. PubMed ID: 17115424
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome.
    Jädersten M; Malcovati L; Dybedal I; Della Porta MG; Invernizzi R; Montgomery SM; Pascutto C; Porwit A; Cazzola M; Hellström-Lindberg E
    J Clin Oncol; 2008 Jul; 26(21):3607-13. PubMed ID: 18559873
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant human erythropoietin in the treatment of multiple myeloma-associated anemia.
    Mittelman M; Zeidman A; Fradin Z; Magazanik A; Lewinski UH; Cohen A
    Acta Haematol; 1997; 98(4):204-10. PubMed ID: 9401498
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant human erythropoietin in the treatment of myelodysplastic syndromes--response patterns.
    Lewinski UH; Floru S; Cohen AM; Mittelmann M
    Leuk Lymphoma; 1994 Sep; 15(1-2):149-52. PubMed ID: 7858493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.